Research programme: targeted nanoparticle therapeutics - Pfizer

Drug Profile

Research programme: targeted nanoparticle therapeutics - Pfizer

Alternative Names: Accurins®; BIND 267; BIND-510; KSP inhibitor accurin; PLK1 inhibitor accurin; PSMA-targeted vincristine - Pfizer

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIND Biosciences
  • Developer BIND Therapeutics; Pfizer
  • Class
  • Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies; Infections
  • No development reported Solid tumours
  • Discontinued Cardiovascular disorders; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 21 Sep 2016 Affilogic and Takeda enter a research collaboration to develop targeted nanoparticle therapeutics
  • 05 May 2016 BIND Therapeutics and Affilogic enter a research collaboration to develop targeted nanoparticle therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top